Precigen Actobio

Industriepark Zwijnaarde 7C
9052 Zwijnaarde
BE
Precigen Actobio
Foundation date
03/07/2006
Sector
#Biotechnology - TherapeuticsSubsector
- #Therapeutics - Drug delivery
- #Therapeutics - Peptides
- #Therapeutics - Proteins
- #Therapeutics - Antibodies
Therapeutic areas
- #Digestive system
- #Diseases of the blood and blood-forming organs - immune disorders
- #Endocrine - nutritional and metabolic diseases
- #Neoplasms / cancer / oncology
- #Respiratory system
Precigen ActoBio™ is a clinical stage biotechnology company pioneering a new class of therapeutic agents created on the ActoBiotics™ platform. These are targeted, microbe-based, specifically designed agents that express and locally deliver potential disease-modifying therapeutics at disease sites including the intestine, the mouth and the nasopharynx, to treat a range of disorders.
We have a strong R&D pipeline and an extensive portfolio of candidates advancing toward clinical development across a number of potential indications.
Precigen ActoBio™ is a wholly-owned subsidiary of Precigen.
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
0604 '23
Innovation for Health 2023
Event by: Hyphen Projects
Latest news
More news-
Imec-onderzoekers leggen basis voor in vivo detectie van traag groeiende hersentumoren, met dank aan hyperspectrale camera
Friday February 3rd 2023
Read more
-
Weber joins Vivactis Group to reinforce its Market Access capabilities
Thursday February 2nd 2023
Read more
-
Mithra CDMO announces collaboration with VaRi Bioscience for the development of a long-acting product in women’s health
Thursday February 2nd 2023
Read more